公开(公告)号：US20240165215A1

公开(公告)日：2024-05-23

申请号：US18344780

申请日：2023-06-29

Applicant: Dynavax Technologies Corporation ,  The Government of the United States, as Represented by the Secretary of the Army

Inventor： Robert S. JANSSEN ,  David Novack ,  Wai Kwan Chung ,  Andrew M. Glenn ,  Lucy A. Ward

IPC: A61K39/02 ,  A61K39/00 ,  A61K39/39 ,  A61P31/04

CPC classification number: A61K39/0291 ,  A61K39/39 ,  A61P31/04 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55561

Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

公开(公告)号：US20210308257A1

公开(公告)日：2021-10-07

申请号：US17351363

申请日：2021-06-18

Applicant: Medigen Vaccine Biologics Corporation ,  Dynavax Technologies Corporation

Inventor： Tsun-Yung KUO ,  Charles CHEN ,  Chung-Chin WU ,  Yi-Jiun LIN ,  Meei-Yun Lin ,  Yu-Chi WU ,  John Darren CAMPBELL ,  Robert S. JANSSEN ,  David NOVACK

IPC: A61K39/215 ,  C07K14/165 ,  C07K14/245

Abstract: The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

公开(公告)号：US20190240323A1

公开(公告)日：2019-08-08

申请号：US15958295

申请日：2018-04-20

Applicant: Dynavax Technologies Corporation

Inventor： Gary S. OTT ,  Robert J. MILLEY ,  Robert L. COFFMAN ,  Radwan KIWAN ,  Holger KANZLER

IPC: A61K39/39 ,  A61K47/61 ,  C07H21/00 ,  A61K47/60 ,  A61K39/12 ,  C07H21/04 ,  A61K31/7125 ,  A61K39/07

CPC classification number: A61K39/39 ,  A61K31/7125 ,  A61K39/07 ,  A61K39/12 ,  A61K47/60 ,  A61K47/61 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/575 ,  C07H21/00 ,  C07H21/04 ,  C12N2730/10134

Abstract: The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides. The present disclosure also relates to uses thereof for stimulating an immune response, and to methods for preparation of the branched chimeric compounds.

公开(公告)号：US20190062329A1

公开(公告)日：2019-02-28

申请号：US16107605

申请日：2018-08-21

Applicant: Dynavax Technologies Corporation

Inventor： Stewart D. CHIPMAN ,  John DEMATTEI ,  Radwan KIWAN ,  Melissa A. KACHURA

IPC: C07D471/04 ,  A61P35/00 ,  A61P31/00

Abstract: Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.

公开(公告)号：US09228184B2

公开(公告)日：2016-01-05

申请号：US13842861

申请日：2013-03-15

Applicant: Dynavax Technologies Corporation

Inventor： Cristiana Guiducci ,  Karen L. Fearon ,  Franck Barrat

IPC: C12N15/117 ,  A61K31/7115 ,  A61K31/712 ,  C07H21/04 ,  C07H21/02 ,  A61K31/711 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/11

CPC classification number: C12N15/11 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/331 ,  C12N2310/344

Abstract: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.

Abstract translation: 本文提供了人Toll样受体（TLR） - 抑制剂和用于具有自身免疫性疾病或炎症性疾病的个体的方法。 本公开的TLR抑制剂是包含TLR7，TLR8和TLR9中的一种或多种的抑制性基序的多核苷酸。

公开(公告)号：US20150297737A1

公开(公告)日：2015-10-22

申请号：US14693727

申请日：2015-04-22

Applicant: Dynavax Technologies Corporation

Inventor： Karen L. FEARON ,  Dino Dina ,  Stephen F. Tuck

IPC: A61K47/48

CPC classification number: A61K47/54 ,  A61K39/12 ,  A61K39/292 ,  A61K47/549 ,  A61K2039/55561 ,  C07H15/18 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/315 ,  C12N2310/332 ,  C12N2310/351 ,  C12N2310/3519 ,  C12N2310/52 ,  C12N2730/10134

Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

Abstract translation: 本发明提供免疫调节化合物和使用免疫调节化合物免疫调节个体的方法。

公开(公告)号：US20140127255A1

公开(公告)日：2014-05-08

申请号：US14030975

申请日：2013-09-18

Applicant: Dynavax Technologies Corporation

Inventor： Karen L. FEARON ,  Dino DINA ,  Stephen F. TUCK

IPC: A61K47/48

CPC classification number: A61K47/48023 ,  A61K39/12 ,  A61K39/292 ,  A61K47/54 ,  A61K47/549 ,  A61K2039/55561 ,  C07H15/18 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/315 ,  C12N2310/332 ,  C12N2310/351 ,  C12N2310/3519 ,  C12N2310/52 ,  C12N2730/10134

Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

Abstract translation: 本发明提供免疫调节化合物和使用免疫调节化合物免疫调节个体的方法。

公开(公告)号：US20250161430A1

公开(公告)日：2025-05-22

申请号：US18838947

申请日：2023-02-28

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ,  DYNAVAX TECHNOLOGIES CORPORATION

Inventor： Florian KRAMMER ,  Peter PALESE ,  Adolfo GARCIA-SASTRE ,  John D. CAMPBELL ,  Paula TRAQUINA ,  Robert L. COFFMAN

IPC: A61K39/145 ,  A61K39/00 ,  A61P37/04

Abstract: In one aspect, provided herein are immunogenic compositions comprising CpG oligonucleotide adjuvant, and a recombinant neuraminidase, wherein the recombinant neuraminidase comprises a globular head domain of influenza virus neuraminidase and a tetramerization domain, and wherein the recombinant neuraminidase lacks influenza virus neuraminidase stalk, transmembrane and cytoplasmic domains. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions. In another aspect, provided herein are methods of immunizing a subject against influenza virus using such immunogenic compositions.

公开(公告)号：US11827641B2

公开(公告)日：2023-11-28

申请号：US17664305

申请日：2022-05-20

Applicant: Dynavax Technologies Corporation

Inventor： Albert Frederick Candia, III ,  Richard Thomas Beresis ,  Robert L. Coffman

IPC: C07D487/04 ,  A61K45/06 ,  C07D231/56 ,  C07D235/18 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D231/56 ,  C07D235/18 ,  C07D519/00

Abstract: The invention relates to compounds of formula (I):




or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

公开(公告)号：US20230092650A1

公开(公告)日：2023-03-23

申请号：US17802361

申请日：2021-03-01

Applicant: Dynavax Technologies Corporation ,  Valneva Austria GmbH

Inventor： John D. Campbell ,  Robert S. Janssen ,  David Novack ,  Christian Taucher ,  Christoph Reinisch ,  Andreas Meinke ,  Michael Möhlen ,  Robert Schlegl ,  Jürgen Heindl-Wruss

IPC: A61K39/215 ,  C12N7/00 ,  A61P31/14

Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.